

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

In vitro and *in vivo* studies on treatment
and prevention of bovine mastitis

A thesis presented in partial fulfilment of the requirements for the degree of
Philosophy Doctor
in
Veterinary Science

at Massey University, Palmerston North,
New Zealand.

Kiro R Petrovski

2011

© Kiro R Petrovski, 2011

Except as provided by the Copyright Act 1994, no part of this publication may be reproduced or stored in a retrieval system in any form or by any means without the prior written permission of the copyright owner

Abstract

Mastitis prevalence on dairy farms depends on the number of infected cows and the duration of each intramammary infection. Strategies aiming to influence these factors are the subject of research presented in this thesis.

Decreasing the duration of infection can be achieved by successfully treating infected quarters. Treatment of mastitis can occur during lactation or in the dry period. Treatment success is influenced by the concentration of antimicrobial achieved at the site of infection and the length of time it is present. The concentration of antimicrobial should exceed the relevant minimal inhibitory concentration. The susceptibility of mastitis-causing organisms varies among geographical areas and over time. New Zealand's susceptibility data demonstrated a high susceptibility to penicillin. A formulation containing this antimicrobial was administered to healthy lactating cows milked once or twice daily. The concentrations of penicillin in milk were above the minimal inhibitory concentrations for the entire inter-dosing interval. Doubling the number of treatments or milking once-a-day resulted in a significantly increased time above the minimal inhibitory concentrations.

The number of new infections is greatest during the early dry period in mature cows and in the pre-calving period in both heifers and mature cows. Pre-partum administration of delayed release antimicrobial formulations in heifers decreased the incidence of clinical mastitis and resulted in better reproductive performance, but not in increased milk production, when compared to control heifers. More effective prevention of new infections within the dry period was achieved by administering a novel teat sealant to mature cows when compared to a commercial teat sealant and untreated controls.

Strategies for shortening the duration of intramammary infections and decreasing the number of affected cows at the start of lactation investigated in this thesis should reduce the prevalence of mastitis on dairy farms in New Zealand.

KEY WORDS: Aetiology, Antibiotic, Antimicrobial, Challenge, Dry period, Experimental challenge, Heifers, Individual Cow Somatic Cell Count, Internal teat sealant, Mastitis, Milking frequency, Penicillin G, Reproductive performance, *Staphylococcus aureus*, *Streptococcus uberis*, *Streptococcus dysgalactiae*, Susceptibility, Time Above the Minimal Inhibitory Concentrations, Udder, Withholding Period.

Acknowledgments

The PhD journey is long and extremely demanding. This thesis represents a multidisciplinary research effort and many people have contributed to its realisation. It is a very difficult task to remember everyone who took a part in helping me through this journey of a PhD candidacy.

I would like to say thanks to my Supervisors: Prof Norman B Williamson (Chief Supervisor), Prof Timothy J Parkinson (Internal Supervisor), Prof Ian J Tucker (External Supervisor) and Assoc Prof Nicolas Lopes-Villalobos (Internal Supervisor) for their guidance and support in this journey.

Thanks also to the co-authors in the various papers: Mohamed Abdalla, Alfredo Caicedo-Caldas, Alejandro (Alex) Grinberg, Richard Laven, Scott McDougall and Paul Rapnicki.

Massey University and particularly the Institute of Veterinary, Animal and Biomedical Sciences are thanked for employing me with financial support from *Bomac a company of Bayer Ltd.*

The experiments reported in this thesis would not have happened without financial support from *Bomac a company of Bayer Ltd* (formerly *Bomac Laboratories Ltd*) and I would like to express my sincere gratitude for their support.

I am indebted to all farm staff in the involved farms, staff at *Gribbles Veterinary Laboratories* Auckland, Christchurch, Dunedin, Hamilton, and Palmerston North, New Zealand and the *Veterinary Diagnostic Laboratory, University of Minnesota*, Minnesota, USA and *MilkTest NZ* (formerly *SAITL Dairy Laboratories*), Hamilton, New Zealand for their friendship, cooperation and interest in my research. Without their full support and cooperation the work reported in this thesis could not have been carried out.

In this thesis five experiments involved the use of dairy cows. For each individual experiment appropriate Animal Ethics Committee was granted by various committees. I would like to say thanks to the committee members for their understanding and approvals of the experiment designs.

It is not possible to list the names of everyone who contributed either directly or indirectly towards this work. Hence, I wish to express my sincere gratitude to all those who discussed matters related to this work and are not mentioned individually. The

anonymous reviewers of the manuscripts are thanked for their constructive criticism of the submitted work.

Some people who assisted me in the preparation of this thesis by taking part in some of the work, helping with agreements for funding, discussion, advice, statistical analysis or just being there when needed:

1. Past and present staff at *Bomac a company of Bayer Ltd*, Auckland, New Zealand: Fadil Al Alawi, Danielle Baxter, Ray Castle, Richard Emslie, Renee Hetherington, Wayne Leech, Connell McLaren, Don McLaren, Lina Ma, Rob Nottingham, Michael Syme, Warren Tully and Bruce Vautier.
2. Past and present staff at *Estendart Ltd*, Palmerston North, New Zealand: Alan Alexander, Hailey Baird, Rene Corner, Kara Eaton, Gilly Evans, Kathryn Hutchinson, Lina Yang, Jude Vautier and many casual staff.
3. Past staff at *Invoco – AgResearch*, Palmerston North: Jeremy Lind, Leonora Pearson and Brian Timms.
4. Past and present staff at *JL Vet Services*, Palmerston North: Jeremy Lind and many casual staff.
5. Past and present farm staff – John Allen, Wendy Allen, Hamish Doohan, Christine Finnegan, Conrad Maeke, Phil Martin and Grant Rudman.
6. Massey University, past and present staff at the *Agricultural Farm Services* – Louise Beazley, Natalie Butcher, Martin Chesterfield, Gareth Evans, Erin Hutchinson, Mark Lawrence, Natalia Martin and Byron Taylor.
7. Massey University, past and present staff at the Institute of Veterinary, Animal and Biomedical Sciences – Frazer Allen, Rukhshana Akhter, Hugh Blair, Andrea Coleman, Georgie Cowley, Gina de Nicolo, Sharron Hawira-Seanoa, Debbie Hill, Litty Kurian, Sue Leathwick, Gayle McKenna, Hamish Mack, Carol Orr, Rebecca Patisson, Quentin Roper, Kevin Stafford, Peter Wildbore and Dianna Willson.
8. Massey University, past and present staff at the *Research Management Services*: Nicola Carse, Mark Cleaver, Don Brown, Leith Hutton and Carolina Tate.
9. Massey University, Turitea campus, Library staff – Chris Good and Bruce White.
10. Massey University, *Large Animal Teaching Unit* – Liz Gillespie and Robin Whitson.
11. Massey University, past and present staff at the Veterinary Teaching hospital – Lesley England, Kevin Lawrence, Jenny Nixey, Alan Thatcher and Jenny Weston.

12. *University of Otago, School of Pharmacy*, past and present staff: Olaf Bork and Zimei Wu.
13. Duncan Hedderley from *The New Zealand Institute for Plant and Food Research Ltd*, Palmerston North.
14. Hassan Hussein from *Cognosco*, Morinsville, New Zealand.
15. Yuanxiang Shi, a visiting scholar from China.

Finally, my family and my dear wife, Ljubica (Bube) for putting up with me during this project.

Table of Contents

Abstract	I
Acknowledgments	III
List of Equations	XIII
List of Figures	XV
List of Tables	XIX
List of Abbreviations	XXV
1. General introduction to the thesis	3
1.1 Background and areas of research of the thesis	3
1.2 Aims of the thesis	10
1.3 Research objectives of the thesis	10
<i>1.3.1 Part One</i>	10
<i>1.3.2 Part Two</i>	11
<i>1.3.3 Part Three</i>	11
<i>1.3.4 Part Four</i>	11
1.4 References	12
Part one	15
2. Introduction to part one: Antimicrobial susceptibility	19
2.1 References	26
3. Culture results from 25,288 milk samples submitted to veterinary diagnostic laboratories from August 2003 to December 2006 in New Zealand	33
3.1 Abstract	33
3.2 Introduction	34
3.3 Materials and methods	35
<i>3.3.1 Microbiological methods</i>	35
<i>3.3.2 Statistical analysis</i>	36
3.4 Results	39
3.5 Discussion	43
3.6 Conclusion	46
3.7 Acknowledgments	46
3.8 References	46

4.	A descriptive analysis of the antimicrobial susceptibility of mastitis-causing bacteria isolated from samples submitted to commercial diagnostic laboratories in New Zealand (2003–2006)	55
4.1	Abstract	55
4.2	Introduction	56
4.3	Materials and methods	57
	4.3.1 <i>Criteria for selection of cases</i>	57
	4.3.2 <i>Microbiological methods</i>	58
	4.3.3 <i>Other records</i>	59
	4.3.4 <i>Statistical analysis</i>	59
4.4	Results	60
	4.4.1 <i>Antimicrobial susceptibility of streptococci</i>	61
	4.4.2 <i>Antimicrobial susceptibility of staphylococci</i>	64
	4.4.3 <i>Antimicrobial susceptibility of other bacterial species</i>	66
4.5	Discussion	66
4.6	Acknowledgements	77
4.7	References	77
5.	Susceptibility to antimicrobials of mastitis-causing <i>Staphylococcus aureus</i>, <i>Streptococcus uberis</i> and <i>Strep. dysgalactiae</i> from New Zealand and the USA as assessed by the disk diffusion test	83
5.1	Abstract	83
5.2	Introduction	84
5.3	Materials and methods	85
	5.3.1 <i>Statistical analysis</i>	87
5.4	Results	89
	5.4.1 <i>Level of susceptibility</i>	94
	<i>Susceptibility of Staphylococcus aureus</i>	96
	<i>Susceptibility of Streptococcus spp</i>	96
	5.4.2 <i>Zones of inhibition</i>	99
	5.4.3 <i>Discordant isolates</i>	104
5.5	Discussion	104
5.6	Conclusion	108
5.7	Acknowledgments	109
5.8	References	109

6.	Correlation of the antimicrobial susceptibility of <i>Staphylococcus aureus</i> and streptococci isolated from bovine milk samples collected in New Zealand when tested by the agar disk diffusion and broth microdilution methods	115
6.1	Abstract	115
6.2	Introduction	116
6.3	Materials and methods	117
6.4	Results	120
	6.4.1 Overall	120
	6.4.2 Ampicillin	123
	6.4.3 Cloxacillin	126
	6.4.4 Enrofloxacin	128
	6.4.5 Neomycin	130
	6.4.6 Oxytetracycline.....	132
	6.4.7 Penicillin	134
6.5	Discussion	136
6.6	Conclusion	139
6.7	Acknowledgments	139
6.8	References	139
	Part two	143
7.	Introduction to Part Two: Effects of milking frequency on pharmacokinetics of penicillin G administered by the intramammary route	147
7.1	References	153
8.	Milking frequency affects the penicillin G elimination times from milk, concentrations and recovery rate following intramammary administration to dairy cows	159
8.1	Abstract	159
8.2	Introduction	160
8.3	Materials and methods	161
	8.3.1 Experimental animals	161
	8.3.2 Treatment and procedures	162
	8.3.3 Statistical analysis	163
8.4	Results	166
	8.4.1 Elimination times	166
	8.4.2 Time above MIC	166

8.4.3	<i>Amount of drug recovered</i>	167
8.5	Discussion	168
8.6	Conclusion	172
8.7	Acknowledgments	172
8.8	References	172
Part three		177
9.	Introduction to Part Three: treatment of heifers for mastitis pre-calving	181
9.1	References	187
10.	Treatment before calving of heifers for mastitis improves their reproductive performance, but not their milk production	195
10.1	Abstract	195
10.2	Introduction	196
10.3	Materials and methods	197
10.3.1	<i>Procedures</i>	197
10.3.2	<i>Statistical Analysis</i>	198
10.4	Results	199
10.4.1	<i>Incidence of clinical mastitis</i>	199
10.4.2	<i>Prevalence of subclinical mastitis</i>	199
10.4.3	<i>Days-in-milk</i>	203
10.4.4	<i>Milk production</i>	203
10.4.5	<i>Reproductive performance</i>	204
10.5	Discussion	205
10.6	Conclusions	208
10.7	Acknowledgments	208
10.8	References	208
Part four		215
11.	Introduction to Part Four: antimicrobial teat sealant for use at drying off	219
11.1	References	224
12.	A preliminary evaluation of the efficacy of two novel internal teat sealant formulations against bacterial challenge in the early dry period	229
12.1	Abstract	229
12.2	Introduction	230
12.3	Materials and methods	230

12.3.1	<i>Cows and treatments administered</i>231
12.3.2	<i>Procedures</i>231
12.3.3	<i>Statistical analysis</i>239
12.4	Results240
12.4.1	<i>Length of dry period</i>240
12.4.2	<i>Palpation scores</i>240
12.4.3	<i>Clinical mastitis</i>242
12.4.4	<i>Genotyping isolates of <i>Streptococcus uberis</i> from clinical cases</i>242
12.4.5	<i>Intramammary infection</i>242
12.4.6	<i>Somatic cells</i>244
12.5	Discussion244
12.6	Acknowledgments246
12.7	References246
13.	Efficacy of a novel internal dry period teat sealant containing 0.5% chlorhexidine against experimental challenge with <i>Streptococcus uberis</i> in dairy cattle251
13.1	Abstract251
13.2	Introduction252
13.3	Materials and methods253
13.3.1	<i>Animals</i>253
13.3.2	<i>Treatment products and treatment administration</i>254
13.3.3	<i>Procedures</i>254
13.3.4	<i>Statistical analysis</i>257
13.4	Results260
13.4.1	<i>Dry period</i>260
13.4.2	<i>Udder palpation scores</i>260
13.4.3	<i>Clinical mastitis during the palpation period</i>261
13.4.4	<i>Milk culture results</i>262
13.5	Discussion264
13.6	Conclusion268
13.7	Acknowledgments268
13.8	References268

14.	General discussion	275
14.1	Part One	275
14.2	Part Two	279
14.3	Part Three	280
14.4	Part Four	281
14.5	Further research needs identified	283
14.6	References	284
15.	List of references	289
16.	Bibliography	315

List of Equations

Equation 1-1 Calculations of the prevalence of mastitis on a dairy farm	3
Equation 4.1 Back-transforming of the model outputs	60

List of Figures

Figure 1.1. Incidence and prevalence of intramammary infections in a herd throughout the season when each infection is of a long duration. The prevalence at the moment of observation is high despite the low incidence	4
Figure 1.2. Incidence and prevalence of intramammary infections in a herd throughout the season when each infection is of a short duration. The prevalence at the moment of observation is low despite the high incidence	5
Figure 1.3. Incidence of intramammary infections through the lactational cycle provided no dry cow therapy is used	8
Figure 2.1. Trend in the number of herds and average herd size from 1974/75 to 2009/10	26
Figure 3.1. Origin of the milk samples submitted for culturing to five commercial laboratories in New Zealand from August 2003 to December 2006	38
Figure 3.2. Monthly isolates of <i>Staphylococcus aureus</i> and <i>Streptococcus uberis</i> as percentage of all samples submitted from August 2003 to December 2006 from winter to autumn	39
Figure 3.3. Monthly isolates of other commonly-isolated mastitis-causing organisms Zealand as percentage of all samples submitted from August 2003 to December 2006 from winter to autumn.	40
Figure 3.4. Percentage of isolates of <i>Streptococcus uberis</i> , <i>Staphylococcus aureus</i> by seasons	42
Figure 5.1 Agar disk diffusion and E-test of <i>Staphylococcus</i> isolate	88
Figure 5.2 Agar disk diffusion and E-test of streptococcal isolate	88
Figure 6.1. Schema of the graphic presentation of each antimicrobial/isolates of causative organism susceptibility testing outcome	120
Figure 6.2. Distribution of susceptibility results of isolates of <i>Staphylococcus aureus</i> or streptococci to ampicillin	125

Figure 6.3. Distribution of susceptibility results of isolates of <i>Staphylococcus aureus</i> or streptococci to cloxacillin	127
Figure 6.4. Distribution of susceptibility results of isolates of <i>Staphylococcus aureus</i> or streptococci to enrofloxacin	129
Figure 6.5. Distribution of susceptibility results of isolates of <i>Staphylococcus aureus</i> or streptococci to neomycin	131
Figure 6.6. Distribution of susceptibility results of isolates of <i>Staphylococcus aureus</i> or streptococci to oxytetracycline	133
Figure 6.7. Distribution of susceptibility results of isolates of <i>Staphylococcus aureus</i> or streptococci to penicillin	135
Figure 8.1. Treatment by the intramammary route using partial insertion technique	163
Figure 8.2. Milk samples for various analysis and reserves	165
Figure 8.3. <i>DeLaval</i> in-line samplers	165
Figure 8.4. Concentrations of procaine penicillin G in milk (mg/kg) in cows treated 3 times and milked once-a-day or twice daily and treated 6 times and milked twice daily	167
Figure 10.1. Moving average (10-daily) of the predicted geometric mean of individual cow somatic cell count in treated and control heifers in their first lactation	201
Figure 10.2. Percentage of treated heifers with high individual cow test-day somatic cell count (ICSCC \geq 200,000/mL) percentage of new infections (change of ICSCC from low to high) and percentage of cured cases (change of ICSCC form high to low) through their first lactation	202
Figure 10.3. Percentage of control heifers with high individual cow test-day somatic cell count (ICSCC \geq 200,000/mL) percentage of new infections (change of ICSCC from low to high) and percentage of cured cases (change of ICSCC form high to low) through their first lactation	203

Figure 10.4. Predicted milk volume using the method of Ali and Schaeffer (1987) in treated and control heifers during their first lactation204

Figure 11.1. Treatment design for the second challenge study220

Figure 12.1 X-ray picture of the location of the internal teat sealant post treatment with the sealant showing as a bright white area within the teat cavity234

Figure 12.2 X-raying of the teats after treatment in order to evaluate the position of the teat sealant as shown in Figure 12.1235

Figure 12.3. Average daily udder palpation score241

Figure 13.1. Survival analysis from treatment to incidence of clinical mastitis during the first 34 days after drying-off262

List of Tables

Table 2.1. Summary of the three general mechanisms of acquired resistance in pathogenic microorganisms	21
Table 2.2. Classification of efflux resistance mechanisms present in pathogenic microorganisms based on the spectrum of activity to various antimicrobial classes and transporter families	22
Table 2.3. Summary of the general mechanisms of intrinsic resistance in pathogenic microorganisms	23
Table 3.1. Counts of mastitis-causing organisms isolated from milk samples submitted to five commercial laboratories in New Zealand from August 2003 to December 2006 after reclassification	37
Table 3.2. Percentage (\pm standard error) of isolation of <i>Streptococcus uberis</i> by year, season and island from milk samples submitted to five commercial laboratories in New Zealand from August 2003 to December 2006	41
Table 3.3. Percentage (\pm standard error) of isolation of <i>Staphylococcus aureus</i> by year, season and island from milk samples submitted to five commercial laboratories in New Zealand from August 2003 to December 2006	41
Supplementary information - Table 3.4. Counts of mastitis-causing organisms isolated from milk samples submitted to five commercial laboratories in New Zealand from August 2003 to December 2006	48
Table 4.1. Number of tests for antimicrobial susceptibility of mastitis-causing bacteria isolated from samples submitted to five commercial laboratories in New Zealand over a 40-month period (2003–2006), categorised by region of origin of sample	58
Table 4.2. Number of tests for antimicrobial susceptibility, and percentage susceptibility, of seven mastitis-causing bacterial pathogens isolated in pure culture, each with >1,000 tests, and of 11 antimicrobials tested against >500 isolates from milk samples submitted to five commercial laboratories in New Zealand over a 40-month period (2003–2006)	62

Table 4.3. Number of tests and estimated percentage susceptibility, with 95% CI, to antimicrobials for isolates of <i>Streptococcus uberis</i> from milk samples submitted to five commercial laboratories in New Zealand over a 40-month period (2003–2006), adjusted for effect of year of testing, island of origin of sample, and the interaction of year and antimicrobial	63
Table 4.4. Number of tests and estimated percentage susceptibility, with 95% CI, to antimicrobials for isolates of <i>Staphylococcus aureus</i> from milk samples submitted to five commercial laboratories in New Zealand over a 40-month period (2003–2006), adjusted for effect of year of testing, island of origin of sample, and the interaction of year and antimicrobial	65
Table 4.5. List of available pharmaceutical products containing a minimum of one antimicrobial authorised for the treatment of bovine mastitis in New Zealand (2009), as indicated on the label’s recommendations	73
Table 5.1. Disk potency of antimicrobials used in the study (µg- micrograms)	87
Table 5.2. Susceptibility of isolates of <i>Staphylococcus aureus</i> and streptococci by country	90
Table 5.3. Susceptibility of streptococcal isolates by country	92
Table 5.4. Prevalence of susceptibility (mean ± SE) of <i>Staphylococcus aureus</i> and streptococci isolated from milk samples collected in New Zealand and the USA to a range of antimicrobials	95
Table 5.5. Prevalence of susceptibility (mean ± SE) of <i>Streptococcus uberis</i> and <i>Strep. dysgalactiae</i> isolated from milk samples collected in New Zealand and the USA to a range of antimicrobials	98
Table 5.6. Diameters of zones of inhibition (mean ± SE) for susceptible and resistant isolates of <i>Staphylococcus aureus</i> and streptococci isolated from milk samples collected in New Zealand and the USA	100
Table 5.7. Diameters of zones of inhibition (mean ± SE) for susceptible and resistant isolates of <i>Streptococcus uberis</i> and <i>Strep. dysgalactiae</i> isolated from milk samples collected in New Zealand and the USA	102

Table 6.1. Interpretive criteria for bacteria isolated from animals (if not stated otherwise based on the Clinical and Laboratory Standards Institute, 2008)	119
Table 6.2. Average sizes of inhibition at agar disk diffusion (mm \pm SE) compared to microdilution test results (μ g/mL) for various antimicrobial and causative organism combinations	122
Table 6.3. Correlation parameters for the zones of inhibition measured using the agar disk diffusion method with the MIC obtained by the broth microdilution method for various antimicrobial/causative organism combinations	124
Table 8.1. Elimination times of penicillin G from milk (means \pm SE) in cows under different milking frequency and treatment regime treated with Lactapen G by the intramammary route	166
Table 8.2. Amount of penicillin G recovered from milk of cows under different milking frequency and treatment regime treated with Lactapen G by the intramammary route	168
Table 9.1. Reported prevalence of intramammary infections in heifers before the first calving based on culture	182
Table 9.2. Prevalence of intramammary infections in heifers around the first calving.	183
Table 9.3. Rate of clinical mastitis in heifers around calving or during the first lactation.	185
Table 10.1. Changes in the percentage of heifers with high individual somatic cell counts High ICSCC; $SCC \geq 200,000$ /mL) from low to high (New infections) and high to low (Cured infections) approximating rates of new infections and cures from subclinical mastitis and the percentage of high ICSCC on test-day in treated and control heifers during their first lactation	200
Table 10.2. Means \pm SE and differences of three reproductive parameters in treated and control heifers	204
Table 11.1. Summary of studies on the efficacy of teat sealants alone and their use in combination with other products	223

Table 12.1. Quarter and teat examination and palpation scores and description (criteria developed by KRP)	236
Table 12.2. Means and standard errors of the lengths of the dry period in days per group	240
Table 12.3. Palpation scores in the first 34 days after drying-off adjusted for the random effect of an individual cow	240
Table 12.4. Effect of treatment on palpation scores in the first 34 days after drying-off	241
Table 12.5. Incidence of clinical mastitis during the palpation period by treatment	242
Table 12.6. Prevalence of quarters with intramammary infection after calving	243
Table 12.7. Summary of the culture results in per cent (and numbers) after calving (D0 - day of calving; D4 - day 4 after calving) for all sampled quarters (including those treated for clinical mastitis during the palpation period)	243
Table 12.8. Means and their standard errors of the somatic cell scores (log of the somatic cell count divided by 1,000) among groups after calving	244
Table 13.1. The concentration of colony-forming units of a <i>Streptococcus uberis</i> S210 strain per millilitre in the challenge broth at different challenge days	255
Table 13.2. Quarter and teat examination and palpation scores and description	255
Table 13.3. Prevalence of infected or non-infected quarters in percent \pm standard errors among groups	259
Table 13.4. Effect of treatment on palpation scores in the first 34 days after drying-off	260
Table 13.5. Distribution of cases of clinical mastitis, the probability of a quarter being affected by clinical mastitis and probability of a quarter of being affected with clinical mastitis caused by the challenge organism in the first 34 days after drying-off	261

Table 13.6. Summary of the culture results in percent (and numbers) among groups263

Table 13.7. Means and 95% confidence intervals of the quarter level infection rate after calving264

List of abbreviations

Abbreviation	Meaning
ACVM	Agricultural Compounds and Veterinary Medicines Group (part of MAF New Zealand)
ATS	Anti-Infective-Containing Internal Teat Sealant
BAGG	Buffered Azide Glucose Glycerol broth
BMSCC	Bulk Milk Somatic Cell Count
CAMP	Christie–Atkins–Munch–Petersen test
CI	Confidence Interval
CLSI	Clinical and Laboratory Standards Institute
CMT	California Mastitis Test
CNS	Coagulase-Negative Staphylococci
DCT	Dry Cow Therapy
EMA	European Medicines Agency
EUCAST	European Committee on Antimicrobial Susceptibility Testing
I	Intermediate Susceptibility
ICSCC	Individual Cow Somatic Cell Count
IU	International Units
kg	Kilogramme
L	Litre
LF	Left Front
Ltd	Limited
µg	Microgram
mg	Milligram
mL	Millilitre
MIC	Minimal Inhibitory Concentration

List of Abbreviations continued

MRL	Maximum Residue Levels
MRSA	Methicillin-Resistant <i>Staphylococcus aureus</i>
NIRD	National Institute for Research in Dairying
OAD	Once-a-Day
PBP	Penicillin Binding Protein
PFGE	Pulse Field Gel Electrophoresis
R	Resistant
RR	Rear Right
S	Susceptible
SAMM	Seasonal Approach to Managing Mastitis
SAS	Statistical Analysis System
SCC	Somatic Cell Count
SCS	Somatic Cell Score
T>MIC	Time above the Minimal Inhibitory Concentrations
TD	Twice daily
WHP	Withholding period
